JPS60185727A - ４−カルバモイルイミダゾリウム−５−オレ−ト製剤の安定化法 - Google Patents

４−カルバモイルイミダゾリウム−５−オレ−ト製剤の安定化法

Info

Publication number
JPS60185727A
JPS60185727A JP59043265A JP4326584A JPS60185727A JP S60185727 A JPS60185727 A JP S60185727A JP 59043265 A JP59043265 A JP 59043265A JP 4326584 A JP4326584 A JP 4326584A JP S60185727 A JPS60185727 A JP S60185727A
Authority
JP
Japan
Prior art keywords
acid
preparation
acidic substance
oleate
carbamoylimidazolium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP59043265A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0137376B2 (enExample
Inventor
Keiichi Kato
啓一 加藤
Kaneo Hara
原　統男
Hisao Tohiki
戸引　久雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Chemical Co Ltd
Original Assignee
Sumitomo Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co Ltd filed Critical Sumitomo Chemical Co Ltd
Priority to JP59043265A priority Critical patent/JPS60185727A/ja
Priority to EP85301164A priority patent/EP0159777A1/en
Priority to CA000475351A priority patent/CA1235065A/en
Priority to ES540907A priority patent/ES8700936A1/es
Priority to KR1019850001346A priority patent/KR850006131A/ko
Publication of JPS60185727A publication Critical patent/JPS60185727A/ja
Publication of JPH0137376B2 publication Critical patent/JPH0137376B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP59043265A 1984-03-05 1984-03-05 ４−カルバモイルイミダゾリウム−５−オレ−ト製剤の安定化法 Granted JPS60185727A (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP59043265A JPS60185727A (ja) 1984-03-05 1984-03-05 ４−カルバモイルイミダゾリウム−５−オレ−ト製剤の安定化法
EP85301164A EP0159777A1 (en) 1984-03-05 1985-02-21 Stabilized 4-carbamoyl-imidazolium-5-olate
CA000475351A CA1235065A (en) 1984-03-05 1985-02-27 Stabilized 4-carbamoyl-imidazolium-5-olate preparations
ES540907A ES8700936A1 (es) 1984-03-05 1985-03-04 Un metodo de producir una composicion farmaceutica estabili-zada
KR1019850001346A KR850006131A (ko) 1984-03-05 1985-03-04 안정화된 제약 조성물

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59043265A JPS60185727A (ja) 1984-03-05 1984-03-05 ４−カルバモイルイミダゾリウム−５−オレ−ト製剤の安定化法

Publications (2)

Publication Number Publication Date
JPS60185727A true JPS60185727A (ja) 1985-09-21
JPH0137376B2 JPH0137376B2 (enExample) 1989-08-07

Family

ID=12659008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59043265A Granted JPS60185727A (ja) 1984-03-05 1984-03-05 ４−カルバモイルイミダゾリウム−５−オレ−ト製剤の安定化法

Country Status (5)

Country Link
EP (1) EP0159777A1 (enExample)
JP (1) JPS60185727A (enExample)
KR (1) KR850006131A (enExample)
CA (1) CA1235065A (enExample)
ES (1) ES8700936A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62252722A (ja) * 1986-01-14 1987-11-04 Chugai Pharmaceut Co Ltd Ｎ−（２−ヒドロキシエチル）ニコチン酸アミド硝酸エステル含有注射剤
WO2009035168A1 (ja) 2007-09-14 2009-03-19 Mbr Co., Ltd. ４－カルバモイル－５－ヒドロキシ－イミダゾール誘導体のスルホン酸塩化合物
WO2013047758A1 (ja) 2011-09-28 2013-04-04 富士フイルム株式会社 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド水和物の結晶及び５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド・３／４水和物の結晶及びその製造方法
JP2013082708A (ja) * 2011-09-28 2013-05-09 Fujifilm Corp ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミド・３／４水和物の結晶及びその製造方法
JP2013082706A (ja) * 2011-09-28 2013-05-09 Fujifilm Corp ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミド水和物の結晶
WO2014112529A1 (ja) * 2013-01-15 2014-07-24 富士フイルム株式会社 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミドの硫酸塩
US8894496B2 (en) 2009-09-28 2014-11-25 Jtekt Corporation Coupling yoke for double cardan joint
WO2019082898A1 (ja) 2017-10-27 2019-05-02 富士フイルム株式会社 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド・３／４水和物の製造方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014026250A2 (pt) * 2013-01-15 2017-06-27 Fujifilm Corp preparação de produto sólido embalado contendo 5-hidroxi-1h-imidazola-4-carboxamida ou sal do mesmo, ou hidrato dos mesmos
SI2946780T1 (sl) 2013-01-15 2017-05-31 Fujifilm Corporation Tableta, ki vsebuje 5-hidroksi-1h-imidazol-4-karboksamid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181731A (en) * 1976-09-07 1980-01-01 Sumitomo Chemical Company, Limited Novel therapeutic application of 4-carbamoyl-5-hydroxyimidazole
DE3176849D1 (en) * 1980-11-05 1988-09-29 Sumitomo Chemical Co Pharmaceutical composition comprising 4-carbamoyl-imidazolium-5-olate

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62252722A (ja) * 1986-01-14 1987-11-04 Chugai Pharmaceut Co Ltd Ｎ−（２−ヒドロキシエチル）ニコチン酸アミド硝酸エステル含有注射剤
WO2009035168A1 (ja) 2007-09-14 2009-03-19 Mbr Co., Ltd. ４－カルバモイル－５－ヒドロキシ－イミダゾール誘導体のスルホン酸塩化合物
US8894496B2 (en) 2009-09-28 2014-11-25 Jtekt Corporation Coupling yoke for double cardan joint
US9108928B2 (en) 2011-09-28 2015-08-18 Fujifilm Corporation Crystal of 5-hydroxy-1H-imidazole-4-carboxamide 3/4 hydrate, method for producing the same and crystal of 5-hydroxy-1H-imidazole-4-carboxamide hydrate
JP2013082706A (ja) * 2011-09-28 2013-05-09 Fujifilm Corp ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミド水和物の結晶
KR20140069052A (ko) 2011-09-28 2014-06-09 후지필름 가부시키가이샤 5-히드록시-1h-이미다졸-4-카르복사미드 수화물의 결정, 5-히드록시-1h-이미다졸-4-카르복사미드·3/4 수화물의 결정 및 그 제조 방법
JP2013082708A (ja) * 2011-09-28 2013-05-09 Fujifilm Corp ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミド・３／４水和物の結晶及びその製造方法
JP2015110644A (ja) * 2011-09-28 2015-06-18 富士フイルム株式会社 ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミド・３／４水和物の結晶及びその製造方法
WO2013047758A1 (ja) 2011-09-28 2013-04-04 富士フイルム株式会社 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド水和物の結晶及び５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド・３／４水和物の結晶及びその製造方法
US9567303B2 (en) 2011-09-28 2017-02-14 Fujifilm Corporation Crystal of 5-hydroxy-1H-imidazole-4-carboxamide hydrate and pharmaceutical composition thereof
WO2014112529A1 (ja) * 2013-01-15 2014-07-24 富士フイルム株式会社 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミドの硫酸塩
JP6001684B2 (ja) * 2013-01-15 2016-10-05 富士フイルム株式会社 ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミドの硫酸塩
US9475778B2 (en) 2013-01-15 2016-10-25 Fujifilm Corporation Sulfate of 5-hydroxy-1H-imidazole-4-carboxamide
WO2019082898A1 (ja) 2017-10-27 2019-05-02 富士フイルム株式会社 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド・３／４水和物の製造方法
US10954196B2 (en) 2017-10-27 2021-03-23 Fujifilm Corporation Method for producing 5-hydroxy-1H-imidazole-4 carboxamide 3/4 hydrate

Also Published As

Publication number Publication date
CA1235065A (en) 1988-04-12
KR850006131A (ko) 1985-10-02
ES540907A0 (es) 1986-11-16
EP0159777A1 (en) 1985-10-30
JPH0137376B2 (enExample) 1989-08-07
ES8700936A1 (es) 1986-11-16

Similar Documents

Publication Publication Date Title
JP4621326B2 (ja) テプレノンの安定化組成物
AU725622B2 (en) Pharmaceutical composition stabilized with a basic agent
CA1338889C (en) Morphine containing composition
AU2005210174B2 (en) New compositions containing quinoline compounds
IE871738L (en) Crystalline oral cephalosporin hydrate
CA2083683C (en) Stable formulation of analapril salt, a process for the preparation thereof and the use thereof
JPS60185727A (ja) ４−カルバモイルイミダゾリウム−５−オレ−ト製剤の安定化法
JP2004511561A (ja) 薬剤組成物
JP2000191516A (ja) 経口固形組成物
JP2916227B2 (ja) ビタミンｂ▲下１▼▲下２▼類含有組成物
IE63051B1 (en) Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
RU2106145C1 (ru) Фармацевтическая композиция и способ ее получения (варианты)
KR20020015327A (ko) 속방성 경구 의약품 조성물
JPH11335302A (ja) 安定な医薬組成物
JP2974550B2 (ja) 経口投与用固体組成物
JP2591235B2 (ja) アルキルシステインまたはその酸付加塩を含有する安定な錠剤
JPH0222225A (ja) 胃酸分泌抑制剤含有固型製剤
EP2164469A2 (en) Stable formulation of amorphous perindopril salts, a process for the preparation thereof on industrial scale and use thereof in the treatment of hypertension
EP0431759B1 (en) Process for the preparation of a ranitidine resin absorbate
JP2531952B2 (ja) フオスホリラ−ゼ阻害剤
JP2003073270A (ja) 安定性および溶出性の良好なプラバスタチンナトリウム錠
KR920008161B1 (ko) 오메프라졸 경구용 약제의 제조방법
WO2022075436A1 (en) A method of producing thyroid hormone-containing formulation
CN1253136A (zh) 噻唑烷类衍生物及其医药用途
JPH05201858A (ja) 固形製剤